Gregory J Kubicek

Summary

Publications

  1. ncbi FDG-PET staging and importance of lymph node SUV in head and neck cancer
    Gregory J Kubicek
    Thomas Jefferson University Hospital, Philadelphia, PA, USA
    Head Neck Oncol 2:19. 2010
  2. ncbi Chemotherapy in head and neck cancer: clinical predictors of tolerance and outcomes
    Gregory J Kubicek
    Department of Radiation Oncology, University of Pittsburgh Medical Center, PA, USA
    Am J Clin Oncol 34:380-4. 2011
  3. ncbi Combined transperineal implant and external beam radiation for the treatment of prostate cancer: a large patient cohort in the community setting
    Gregory J Kubicek
    Department of Radiation Oncology, University of Pittsburgh Medical Center, Pittsburgh, PA
    Brachytherapy 10:449-53. 2011
  4. ncbi Importance of treatment institution in head and neck cancer radiotherapy
    Gregory J Kubicek
    Department of Radiation Oncology, Jefferson Medical College, Thomas Jefferson University, Philadelphia, PA 19147, USA
    Otolaryngol Head Neck Surg 141:172-6. 2009
  5. ncbi New advances in high-technology radiotherapy for head and neck cancer
    Gregory J Kubicek
    Department of Radiation Oncology, Jefferson Medical College, Thomas Jefferson University, Philadelphia, PA 19107, USA
    Hematol Oncol Clin North Am 22:1165-80, viii. 2008
  6. ncbi Phase I trial using proteasome inhibitor bortezomib and concurrent temozolomide and radiotherapy for central nervous system malignancies
    Gregory J Kubicek
    Department of Radiation Oncology, Jefferson Medical College of Thomas Jefferson University, Philadelphia, PA, USA
    Int J Radiat Oncol Biol Phys 74:433-9. 2009
  7. ncbi Do elderly patients experience increased perioperative or postoperative morbidity or mortality when given neoadjuvant chemoradiation before esophagectomy?
    Shannon E Fogh
    Department of Radiation Oncology, University of California, San Francisco, CA 94143, USA
    Int J Radiat Oncol Biol Phys 80:1372-6. 2011
  8. ncbi PSA decrease during combined-modality radiotherapy predicts for treatment outcome
    Gregory J Kubicek
    Department of Radiation Oncology, Jefferson Medical College of Thomas Jefferson University, Philadelphia, PA, USA
    Int J Radiat Oncol Biol Phys 78:759-62. 2010

Detail Information

Publications8

  1. ncbi FDG-PET staging and importance of lymph node SUV in head and neck cancer
    Gregory J Kubicek
    Thomas Jefferson University Hospital, Philadelphia, PA, USA
    Head Neck Oncol 2:19. 2010
    ..The NCCN guidelines do not recommend FDG-PET as a part of standard workup. The purpose of this report is to examine the role of FDG-PET imaging in altering management and providing prognostic information for HNC...
  2. ncbi Chemotherapy in head and neck cancer: clinical predictors of tolerance and outcomes
    Gregory J Kubicek
    Department of Radiation Oncology, University of Pittsburgh Medical Center, PA, USA
    Am J Clin Oncol 34:380-4. 2011
    ..However, little data are available regarding the best chemotherapy agent and dosing, or factors associated with chemotherapy compliance...
  3. ncbi Combined transperineal implant and external beam radiation for the treatment of prostate cancer: a large patient cohort in the community setting
    Gregory J Kubicek
    Department of Radiation Oncology, University of Pittsburgh Medical Center, Pittsburgh, PA
    Brachytherapy 10:449-53. 2011
    ..Our purpose was to report the results of combined modality therapy from a single institution in the community setting...
  4. ncbi Importance of treatment institution in head and neck cancer radiotherapy
    Gregory J Kubicek
    Department of Radiation Oncology, Jefferson Medical College, Thomas Jefferson University, Philadelphia, PA 19147, USA
    Otolaryngol Head Neck Surg 141:172-6. 2009
    ..Our goal is to determine if these potential AC advantages correspond to a difference in treatment outcome...
  5. ncbi New advances in high-technology radiotherapy for head and neck cancer
    Gregory J Kubicek
    Department of Radiation Oncology, Jefferson Medical College, Thomas Jefferson University, Philadelphia, PA 19107, USA
    Hematol Oncol Clin North Am 22:1165-80, viii. 2008
    ..Some of these advances are discussed in this article...
  6. ncbi Phase I trial using proteasome inhibitor bortezomib and concurrent temozolomide and radiotherapy for central nervous system malignancies
    Gregory J Kubicek
    Department of Radiation Oncology, Jefferson Medical College of Thomas Jefferson University, Philadelphia, PA, USA
    Int J Radiat Oncol Biol Phys 74:433-9. 2009
    ..To evaluate the toxicity and response rate of bortezomib with concurrent radiotherapy and temozolomide in the treatment of patients with central nervous system malignancies...
  7. ncbi Do elderly patients experience increased perioperative or postoperative morbidity or mortality when given neoadjuvant chemoradiation before esophagectomy?
    Shannon E Fogh
    Department of Radiation Oncology, University of California, San Francisco, CA 94143, USA
    Int J Radiat Oncol Biol Phys 80:1372-6. 2011
    ....
  8. ncbi PSA decrease during combined-modality radiotherapy predicts for treatment outcome
    Gregory J Kubicek
    Department of Radiation Oncology, Jefferson Medical College of Thomas Jefferson University, Philadelphia, PA, USA
    Int J Radiat Oncol Biol Phys 78:759-62. 2010
    ..Although reports have focused on the importance of pretreatment PSA levels, doubling time, and posttreatment nadirs, there is little information on the value of PSA during the course of radiotherapy...